<DOC>
	<DOCNO>NCT02905981</DOCNO>
	<brief_summary>The main purpose determine whether Triferic , administer orally Shohl 's solution , safe effective treatment iron-refractory iron-deficiency anemia ( IRIDA ) .</brief_summary>
	<brief_title>Triferic IRIDA Protocol</brief_title>
	<detailed_description>This open label , 3-period study assess safety , efficacy , pharmacokinetics Triferic Shohl 's solution administer orally patient IRIDA . A total 28 patient stratify 4 age group ( age 0 &lt; 6 year , age 6 &lt; 12 year , age 12 &lt; 18 year , age &gt; =18 year ) study . Total participation study 4 week ( Period 1 ) 12 month ( Periods 1 , 2 , 3 ) , depend upon many Periods patient participates . Following screening , Period 1 ( iron absorption test ) patient undergo oral iron absorption test 3 visit confirm adequately absorb iron Triferic administer Shohl 's solution ( 'Triferic responder ' : patient maximal increase baseline serum iron concentration &gt; 100 μg/dL follow oral Shohl 's solution Triferic dose ) . The 'Triferic responder ' Period 1 invited participate Period 2 ( dose titration ) . The patient receive Shohl 's solution Triferic orally 3 time per day 4 month , titrate need base laboratory result patient tolerance , determine whether hemoglobin level respond treatment . Period 2 'hemoglobin responder ' ( patient increase baseline Hgb concentration ≥1.0 g/dL Visit 9 ) invite participate period 3 . In Period 3 patient receive Shohl 's solution Triferic orally 3 time per day additional 6 month determine whether hemoglobin response observe Period 2 sustainable . During Period 3 , Shohl 's solution Triferic dose frequency may continue titrate need base laboratory result patient tolerance . A follow-up visit occur approximately 1 week last complete Period study visit , regardless Period patient completes study .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Adult patient provide informed consent sign informed consent form . For pediatric patient , parents/legal guardian patient ability understand requirement study demonstrated willingness child comply study procedure sign informed consent form . Where applicable , assent pediatric patient also obtain study procedure prior studyrelated activity . 2 . Patient history congenital hypochromic microcytic anemia . 3 . Patient mean corpuscular volume ( MCV ) ≤75 fL screening . 4 . Patient serum transferrin saturation ≤15 % screening . 5 . Patient history incomplete response oral iron therapy . 6 . Patient history incomplete response intravenous iron administration . 7 . Patient history hepcidin concentration ≥10 ng/mL ( 3.58 nM ) iron supplement , adjust specific hepcidin assay use least 1 standard deviation ( SD ) great mean patient irondeficiency anemia . 8 . Patient document homozygous compound heterozygous pathogenic mutation TMPRSS6 CLIAcertified laboratory . 9 . Patient appropriate laboratory value disease state screening ( per investigator judgment ) . 10 . Patient significant abnormal finding physical examination screen would preclude participation study ( per investigator judgment ) . 11 . If patient female , must prepubertal , documented surgical sterilization ≥2 year prior screen , practice adequate birth control . All female patient 9 year age older , also reach menarche age 9 year , must negative serum pregnancy test screening . It investigator 's responsibility determine whether patient adequate birth control study participation . 1 . Patient IV oral iron supplement within 2 week prior Visit 2 . 2 . Patient blood transfusion within 3 month prior Visit 2 . 3 . Patient receive intravenous oral antibiotic antifungal infectious process . Prophylactic antibiotic administer regular basis allow . Otherwiseeligible patient may rescreened recover acute illness . 4 . Patient body weight &lt; 11 lb ( 5 kg ) screening . 5 . Patient participate investigational drug study within 30 day prior Visit 2 . 6 . Patient condition , opinion investigator , likely prevent patient comply successfully complete protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>IRIDA</keyword>
	<keyword>Triferic</keyword>
	<keyword>soluble ferric pyrophosphate</keyword>
	<keyword>Shohl 's solution</keyword>
</DOC>